KKKarl C. Kronmann

Karl C. Kronmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Karl C. Kronmann has a total of 211 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association between depression and HIV treatment outcomes in a US military population with HIV infection

    by Brandon Carney, Colton Daniels, Xiaohe Xu, Thankam Sunil, Anuradha Ganesan, Jason M. Blaylock, Karl C. Kronmann, Christina Schofield, Tahaniyat Lalani, Brian Agan, et al.

    Background: Depression is common among HIV-infected individuals and may contribute to suboptimal adherence to antiretroviral therapy (ART) and subsequent inability to attain viral load (VL) suppression. We evaluated associations between depression, self-reported adherence, and longitudinal HIV treatment outcomes in US Military HIV Natural History Study (NHS) participants with and without depression. Methods: Male NHS participants with available ICD-9 data for mental health diagnoses, Center for Epidemiological Studies Depression (CES-D) measures, and self-reported adherence (SRA) were included. ART use was defined as ART initiation between 2006 and 2010, with follow-up through 2015. SRA was defined as taking 95% of ART doses and continuous ART was defined as longitudinal ART use with gaps < 30 days. Continuous VL suppression was defined as maintaining VLs < 200 c/mL on ART. To analyse the association between depression and HIV treatment outcomes, latent class analysis was used to create classes of depression trajectories: low depression (LD), recent onset depression (ROD) and high Depression (HD). Results: Participants had a mean age of 32 (± 8.3) years at HIV diagnosis, and similar proportions were Caucasian (44.3%) or African American (40.8%). Overall, older participants at HIV diagnosis had greater odds of having 95% self-reported adherence (OR 1.06, 95% CI 1.02–1.12), and African Americans had lower odds (OR 0.41, 95% CI 0.22–0.76) compared to Caucasians (OR 1.49, 95% CI 0.52–4.28). However, there was no difference in SRA by depression trajectory. Participants with HD had an increased odds of taking ART continuously (OR 1.75, 95% CI 0.99–3.09), and those with ROD had significantly higher odds of virologic failure (OR 0.58, 95% CI 0.38–0.91). Conclusions: Although there was no observed association between depression and SRA, participants with ROD had lower odds of attaining the HIV treatment goal of VL suppression. Continued efforts to identify and aggressively manage mental health disorders is important to success along the HIV care continuum.


  • Open Access

    Disaster Response to Puerto Rico: An Internal Medicine Humanitarian Response Aboard the USNS COMFORT

    by Benjamin Vipler, David Nissan, Nicholas Darling, Daniel Dean, A Dawn Pettebone, Thomas Hicks, Cynthia Sikorski, Edwin Landaker, Nelle Linz, Karl Kronmann, et al.

    The USNS COMFORT (T-AH 20) hospital ship supports three missions: medical care of the warfighter, scheduled humanitarian assistance, and disaster response. One of the COMFORT’s most impactful disaster response missions occurred in 2010 when the ship deployed in support of Operation Unified Response after a 7.0 magnitude earthquake devastated Haiti. Amundson et al detailed their experience and the capabilities of the 1,000-bed hospital ship.1 On September 20, 2017, Hurricane Maria struck the territory of Puerto Rico as a Category 4 storm, resulting in a humanitarian crisis. On September 29, with as short as 24-hour notice, COMFORT crew and an additional personnel attachment deployed to provide assistance. Hospital ships provide humanitarian support during disaster relief missions similar to terrestrial resources such as Army Combat Support Hospitals (CSHs) and Air Force Expeditionary Medical Support Health Response Teams (EMEDS), both of which were also deployed to Puerto Rico. These mobile healthcare venues’ missions are to fill any gaps in medical care while the host nation recovers.


    • 1 August 2018
      • Vol. 25  (8) , 5-7

    Brief report: Pre- and post-deployment prevalence of Staphylococcus aureus colonization among U.S. Navy submariners.

    by Eugene V Millar, Kristina J St Clair, Carey D Schlett, Jason W Bennett, Gina R Virgilio, Karl Kronmann, Tahaniyat Lalani


  • Open Access

    Prevalence of enteric infections among hospitalized patients in two referral hospitals in Ghana

    by R. Akuffo, G. Armah, M. Clemens, K. C. Kronmann, A. H. Jones, P. Agbenohevi, K. Sagoe, N. Puplampu, N. Talla Nzussouo, W. Ampofo, et al.

    Diarrhea is an important cause of morbidity and mortality worldwide. In Africa and Ghana in particular, it is estimated to contribute directly to 19 and 25% of pediatric mortality among children under 5 years, respectively. Surveillance for hospitalized acute diarrheal illness was initiated in November 2010 through October 2012 in a referral hospital in southern Ghana, and a teaching hospital in northern Ghana. Consenting hospitalized patients who met a standardized case definition for acute diarrheal illness provided demographic and epidemiologic data. Stool samples were collected and tested by culture for bacteria and by enzyme immunoassays for a panel of viruses and parasites. A total of 429 patients were enrolled; 216 (50.3%) were under 5 years, and 221 (51.5%) were females. Stool samples were received from 153 patients. Culture isolates included Shigella sp., Salmonella spp., Plesiomonas sp. and Vibrio cholerae. Of 147 samples tested for viruses, 41 (27.9%) were positive for rotaviruses, 11 (7.5%) for astroviruses, 10 (6.8%) for noroviruses, and 8 (5.4%) for adenoviruses. Of 116 samples tested for parasitic infections; 4 (3.4%) were positive for Cryptosporidium sp. and 3 (2.6%) for Giardia lamblia. Of the enrolled patients, 78.8% had taken antibiotics prior to sample collection. Diarrheal pathogens were identified across all ages, however, predominantly (81%) in the children under 5 years of age. This study also detected high antibiotic use which has the potential of increasing antibiotic resistance. The most common enteric pathogen detected (49.4%) was rotavirus.


  • Open Access

    Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-Immune Adults: A Phase 1, Double-Blinded Placebo Controlled Dosage Escalation Study

    by Kwadwo A. Koram, Bright Adu, Josephine Ocran, Yaa S. Karikari, Susan Adu-Amankwah, Michael Ntiri, Benjamin Abuaku, Daniel Dodoo, Ben Gyan, Karl C. Kronmann, et al.

    The erythrocyte binding antigen region II (EBA-175 RII) is a Plasmodium falciparum ligand that mediates erythrocyte invasion and is considered an important malaria vaccine candidate. A phase Ia trial in malaria naïve adults living in the United States found the recombinant non-glycosylated vaccine antigen, EBA-175 RII-NG adjuvanted with aluminium phosphate to be safe, immunogenic and capable of inducing biologically active antibodies that can inhibit parasite growth in vitro. The aim of the current study was to assess the safety and immunogenicity of this vaccine in malaria exposed semi-immune healthy adults living in a malaria endemic country, Ghana. In this double-blinded, placebo controlled, dose escalation phase I trial, eighteen subjects per group received ascending dose concentrations (5 μg, 20 μg or 80 μg) of the vaccine intramuscularly at 0, 1 and 6 months, while 6 subjects received placebo (normal saline). The primary end point was the number of subjects experiencing Grade 3 systemic or local adverse events within 14 days post-vaccination. Serious adverse events were assessed throughout the study period. Blood samples for immunological analyses were collected at days 0, 14, 28, 42, 180 and 194. A total of 52 subjects received three doses of the vaccine in the respective groups. No serious adverse events were reported. The majority of all adverse events reported were mild to moderate in severity, with local pain and tenderness being the most common. All adverse events, irrespective of severity, resolved without any sequelae. Subjects who received any of the EBA-175 RII-NG doses had high immunoglobulin G levels which moderately inhibited P. falciparum growth in vitro, compared to those in the placebo group. In conclusion, the EBA-175 RII-NG vaccine was safe, well tolerated and immunogenic in malaria semi-immune Ghanaian adults. Its further development is recommended. ClinicalTrials.gov. Identifier: NCT01026246


    • 11 September 2016
      • p. 29-37

    Honey Bee Swarms Aboard the USNS Comfort: Recommendations for Sting Prevention, Swarm Removal, and Medical Readiness on Military Ships.

    by James C Dunford, Karl C Kronmann, Luke R Peet, Jeffrey D Stancil

    The article provides observations of multiple honey bee (Apis mellifera) swarms aboard the USNS Comfort (TAH-20) during the Continuing Promise 2015 mission. A brief overview of swarming biology is given along with control/removal recommendations to reduce sting exposures. The observations suggest that preventive medicine personnel should provide adequate risk communications about the potential occurrence of bee swarms aboard military ships, and medical department personnel should be prepared for the possibility of treating of multiple sting exposures, especially in the Southern Command Area of Operations where the Africanized genotype of A mellifera is common.


  • Open Access

    A comparison of compliance rates with anti-vectorial protective measures during travel to regions with dengue or chikungunya activity, and regions endemic forPlasmodium falciparummalaria

    by Tahaniyat Lalani, Heather Yun, David Tribble, Anuradha Ganesan, Anjali Kunz, Mary Fairchok, Elizabeth Schnaubelt, Jamie Fraser, Indrani Mitra, Karl C. Kronmann, et al.

    Background. There is limited information on compliance rates with anti-vectorial protective measures (AVPMs) during travel to countries with risk of dengue and chikungunya. We evaluated differences in mosquito exposures, and factors associated with AVPM compliance in travellers going to countries where the principal mosquito-borne infectious disease threat is falciparum malaria and those where risk of dengue or chikungunya predominates. Methods. Department of Defence beneficiaries with planned travel to regions where the predominant mosquito-borne infection is falciparum malaria, and those with predominantly dengue or chikungunya risk, were included. Regions were divided into three groups: ‘high-risk falciparum malaria’, ‘low-risk falciparum malaria’ and ‘chikungunya/dengue risk’. Demographics, trip characteristics, arthropod exposure and AVPM compliance were captured using pre- and post-travel surveys. Skin repellent compliance was defined as self-reported use, categorized as ‘often/every day’. A logistic regression model was used to estimate factors associated with AVPM compliance. Results. 183 (9%), 185 (9%) and 149 (7%) travelled to high and low falciparum malaria risk regions, and chikungunya/dengue risk regions, respectively. Overall, 53% (95% CI: 48–57%) and 16% (95% CI: 12–19%) were compliant with repellent use on skin and clothing, respectively. Daytime bites were reported more frequently in chikungunya/dengue risk regions than high malaria risk regions (37% vs. 10%), while night time bites were frequently in high malaria risk regions (53% vs 20%; P < 0.001). Compliance with skin repellents was associated with female gender [RR: 1.54 (95% CI: 1.05–2.28)], observing mosquitoes during travel [RR: 2.77 (95% CI: 1.76–4.36)] and travel during the rainy season [RR: 2.45 (95% CI: 1.66–3.71)]). Conclusions. Poor AVPM compliance was observed in the overall cohort. Compliance with skin repellent use was associated with female gender, observing mosquitoes and travelling during the rainy season, and was not associated with the risk of malaria or chikungunya/dengue at the travel destination.


  • Open Access

    Biosecurity measures to reduce influenza infections in military barracks in Ghana

    by Prince Godfred Agbenohevi, John Kofi Odoom, Samuel Bel-Nono, Edward Owusu Nyarko, Mahama Alhassan, David Rodgers, Fenteng Danso, Richard D Suu-Ire, Joseph Humphrey Kofi Bonney, James Aboagye, et al.


  • Open Access

    A SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum clinical isolates to a panel of anti-malarial drugs

    by Neils B Quashie, Nancy O Duah, Benjamin Abuaku, Lydia Quaye, Ruth Ayanful-Torgby, George A Akwoviah, Margaret Kweku, Jacob D Johnson, Naomi W Lucchi, Venkatachalam Udhayakumar, et al.

    Based on report of declining efficacy of chloroquine, Ghana shifted to the use of artemisinin-based combination therapy (ACT) in 2005 as the first-line anti-malarial drug. Since then, there has not been any major evaluation of the efficacy of anti-malarial drugs in Ghana in vitro. The sensitivity of Ghanaian Plasmodium falciparum isolates to anti-malarial drugs was, therefore, assessed and the data compared with that obtained prior to the change in the malaria treatment policy.